MindWalk Holdings (NASDAQ: $HYFT) is a bio-native AI company that aims to transform drug discovery and development. It is powered by its patented HYFT® technology and the LensAI™ platform. On Monday, December 15, 2025, MindWalk released its Q2 fiscal 2025 results. Let us take a deep dive into those results.
MindWalk Q2 Results
For the second quarter of fiscal 2026, MindWalk reported a quarterly loss of $0.05, bigger than the $0.01 loss estimated by analysts. However, it was an improvement from the $0.07 loss per share reported a year ago.
Revenue came in at $2.97 million in Q2, missing estimates by 25.68%. The figure was also lower than the reported revenue of $4.49 million a year ago. The company has failed to beat consensus revenue estimates in the past four quarters. In its earnings report, the company highlighted sequential growth in continuing operations following a divestiture, though total reported revenue declined and consensus expectations were missed.
Adjusted EBITDA loss narrowed modestly in the October quarter. Adjusted EBITDA loss was approximately $1.8 million USD, compared with about $1.9 million USD in the prior-year period. While the improvement reflects tighter cost controls and operating leverage, the company remains meaningfully unprofitable at the EBITDA level, underscoring the need for sustained revenue growth to reach breakeven.
MindWalk ended the quarter with approximately $12.2 million USD in cash and cash equivalents, inclusive of proceeds from the divestiture of its former Netherlands operations. The cash balance provides near-term operating flexibility, but it is non-recurring in nature, as a meaningful portion stems from asset sales rather than core operating cash flow.
Strategic Highlights
MindWalk completed its rebranding and consolidated its operating units under the HYFT Nasdaq ticker. It welcomed a new CFO, Scott Areglado, and a new Chief Business Officer, Dr. Thomas Lynch. The company has also begun the formation of a Cayman Islands corporation with Walkers law firm that will house segregated portfolios for each of their AI driven programs. That will allow investors to participate in individual portfolios instead of via the public company.
Commenting on the company’s recent achievements, MindWalk CEO Dr. Jennifer Bath stated, “We advanced our GLP1 receptor agonists and identified a companion longevity pathway, while our research uncovered a conserved dengue epitope that could underpin a universal vaccine.”
Market Performance
Following the Q2 results, MindWalk shares were up 1.7% to $1.80 a few minutes to the closing bell, on Monday, December 15, 2025. Year to date, the stock is up 336.89%, while over the past year, the stock is up 346.65%. The stock has gained 7.14% over the past month.
Two analysts give the stock a buy rating, forecast a median price of $3.94, which is a 122.22% upside. The analysts forecast a wide range of prices, with a high of $4.93 and a low of $2.95.
Is MindWalk A Buy In December 2025?
Analysts give MindWalk a strong buy rating, with a focus on its AI/biotech potential. For investors seeking companies in the high growth potential section of AI and biotech, this could potentially be a great addition to their portfolio.
Click Here for Updates on HYFT Invest – It’s 100% FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Please read our Full Disclaimer: https://dexwirenews.com/disclaimer/
